News
SGMT
10.83
+9.95%
0.98
Weekly Report: what happened at SGMT last week (1026-1030)?
Weekly Report · 11/02 10:19
Weekly Report: what happened at SGMT last week (1019-1023)?
Weekly Report · 10/26 10:19
Sagimet Biosciences Inc. Announces Clinical Updates for Denifanstat and TVB-3567
NASDAQ · 10/22 15:12
Sagimet Biosciences Begins Pivotal Phase 3 Study Of Denifanstat In Acne Patients
NASDAQ · 10/22 15:07
Sagimet announces dosing of first patient in AURORA study
TipRanks · 10/22 14:46
H.C. Wainwright views Sagimet dosing news as ‘incrementally positive’
TipRanks · 10/22 14:45
Sagimet Maintains Buy Rating as Phase 3 AURORA Trial Advances and $28 Price Target Remains Unchanged
TipRanks · 10/22 14:45
Analysts Offer Insights on Healthcare Companies: Sagimet Biosciences, Inc. Class A (SGMT) and Revolution Medicines (RVMD)
TipRanks · 10/22 12:50
Sagimet Biosciences Highlights Progress in Acne FASN Pipeline
TipRanks · 10/22 11:48
Sagimet Biosciences Doses First Patient In AURORA, Pivotal U.S. Phase 3 Clinical Trial Of Denifanstat In Adults With Moderate To Severe Acne
Benzinga · 10/22 11:03
Sagimet Biosciences: The U.S. Acne Trial Is A Replication Exercise, Not A Discovery Bet
Seeking Alpha · 10/21 12:35
Tuesday's ETF Movers: XBI, CRAK
NASDAQ · 10/20 16:25
Weekly Report: what happened at SGMT last week (1012-1016)?
Weekly Report · 10/19 10:19
Weekly Report: what happened at SGMT last week (1005-1009)?
Weekly Report · 10/12 10:24
Sagimet Biosciences To Present 52-Week Results From Its Phase 3 ASC40-304 Open-Label Extension Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris At The 2026 Fall Clinical Dermatology Conference, October 8-11
Benzinga · 10/09 11:15
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
Barchart · 10/09 06:00
Notable Monday Option Activity: ONT, NET, SGMT
NASDAQ · 10/05 19:27
Analysts Are Bullish on Top Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Sagimet Biosciences, Inc. Class A (SGMT)
TipRanks · 10/05 10:50
Sagimet Biosciences Price Target Maintained With a $29.00/Share by HC Wainwright & Co.
Dow Jones · 10/05 10:25
Weekly Report: what happened at SGMT last week (0928-1002)?
Weekly Report · 10/05 10:24
More
Webull provides a variety of real-time SGMT stock news. You can receive the latest news about Sagimet Biosciences Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SGMT
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.